Metabolism, Weight Loss
Conditions
Keywords
metabolism, obesity, mentation
Brief summary
This study is to evaluate the physical and cognitive effects of a 15 min per day novel breathing and mindfulness moving-meditation program on metabolism, cognition, and emotion health. It is thought that the breathing and movement program will increase basal metabolism, facilitate fat loss, and decrease depressive behaviors. Anthropometric, blood chemistries, and cognitive measures of depression, sleep, and hunger will be measured over a two-month interventional program.
Detailed description
Subjects will be randomized into two groups, an active group and control group. For the first 30 days, the active group will follow the movement/breath program and the controls will be instructed not to change their lifestyle (no change in diet, and no change in exercise / physical activities). The technicians taking measurements will be blinded as to which participants are actives vs controls. The following 30 days' intervention will consist of continuing the Phase I interventions combined with implementing the behavior change strategies on 2 to 3 habit changes self-selected from a list of 30 top bad habits that contribute to weight gain and undermine one's ability to lose weight with the control group again not changing any lifestyle activities. Measurements: Measurements will be taken at the start (baseline), 10 days, 30 days, and 60 days of intervention with the measurement days scheduled to evaluate people completing 10 full days of the program, 30 full days, and 60 full days respectively. Measurements taken at each interval to include weight, body composition (lean mass & fat percentages), anthropometric measurements (umbilicus, hips, right thigh, right upper arm), pO2, resting heart rate, HRV, blood pressure, pulmonary health (i.e., O2 max, spirometry), hunger, sleep, and depression rating (by self-assessment survey scale). Serum chemistry for basic metabolic panel, inflammatory markers, and lipids, hematology for oxygen carrying capacity and gross immune response, Human Growth Factor production via ELISA quantification, imaging ultrasound to measure subcutaneous fat thickness at the areas of girth measurements, DEXA for overall and targeted areas body composition, and resting metabolic rate via oxygen plethysmograph.
Interventions
OTHERDeep breathing with Yoga positioning
Deep breathing with yoga positioning 10min in morning, 1 minute noon, and 1 minute evening (diner)
Sponsors
Touro University Nevada
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Investigator, Outcomes Assessor)
Masking description
Investigators doing data collection will not know which subjects are interventional and which are controls. Outcomes assessor will not be aware of which group of subjects were interventional and which did not participate in intervention.
Intervention model description
A randomized control group, investigator blinded, repeated measure interventional program.
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-70 years * Body Mass Index at or above 27 * Stable weight past 3 months * able to stand for 10 minutes * Able to lift arms overhead
Exclusion criteria
* Chronic Obstructive Pulmonary Disease * acute respiratory distress * supplemental oxygen use * inability to stand, flex trunk, or move arms overhead * Pacemaker implant * Taking beta blocking medications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change rom baseline in body Weight | Baseline, 10 days, 30 days, and 60 days. | Weight in kilograms |
| Change from baseline in Body Mass Index | Baseline, 10 days, 30 days, and 60 days. | DEXA Measurement of % total fat |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| VO2 at rest, Oxygen consumption at rest-resting metabolic rate(RMR) | Baseline, 10 days, 30 days, and 60 days. | Oxygen consumption via oxygen plethysmograph |
| Human Growth Hormone - Metabolic rate | baseline, 10 days, 30 days, 60 days | Measurement of Human Growth Hormone |
| Respiratory quotient (RQ) - metabolic rate | Baseline, 10 days, 30 days, and 60 days. | CO2 eliminated/O2 consumed |
| lipid panel - metabolic rate | Baseline, 10 days, 30 days, and 60 days. | Total cholesterol, high density lipids, low density lipids, triglycerides |
Other
| Measure | Time frame | Description |
|---|---|---|
| Depression | Baseline, 10 days, 30 days, and 60 days. | Hamilton Depression Rating Scale (HAM-D) depression index self reported survey scored 0-62 with higher score indicating a worse outcome. |
| stress level - autonomic function | Baseline, 10 days, 30 days, 60 days | Heart Rate Variability |
| Sleep | Baseline, 10 days, 30 days, and 60 days. | Insomnia Severity Index (ISI) self reported survey scored 0-28 with higher score indicating worse outcome. |
Countries
United States
Outcome results
None listed